| Ambetter Health Texas Wellcare Allwell Medicare Clinical | Hyaluronate Derivatives (Viscosupplementation) | 2026-01-01 |
| Ambetter Health Texas Wellcare Allwell Medicare Clinical | D. Centene clinical policy | 2026-01-01 |
| UHC UMR Medical and Drug | FcRn Blockers (Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC UMR Medical and Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Surest Medical and Drug | FcRn Blockers (Rystiggo®, Vyvgart®, & Vyvgart Hytrulo®) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Surest Medical and Drug | Rituximab (Riabni®, Rituxan®, Ruxience®, & Truxima®) – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Abnormal Uterine Bleeding and Uterine Fibroids – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Apheresis – Commercial and Individual Exchange Medical Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Botulinum Toxins A and B – Commercial Medical Benefit Drug Policy | 2026-01-01 |
| UHC Commercial Medical & Drug | Breast Reconstruction – Commercial and Individual Exchange Medical Policy | 2026-01-01 |